In 2011 the FDA approved anti- cytotoxic T lymphocyte-associated protein 4 (CTLA4) mAb (ipilimumab) for the indication of metastatic melanoma, based on significant improved overall survival in Phase III trials [4, 5]. This evidence concerns the gene CTLA4 and metastatic melanoma.